Bates Shannon M, Weitz Jeffrey I
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1491-500. doi: 10.1161/01.ATV.0000084827.77945.66. Epub 2003 Jul 3.
The limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs for prevention and treatment of both venous and arterial thromboembolism. After a brief review of thrombogenesis and its regulation, this study focuses on new anticoagulant agents in more advanced stages of clinical testing.
传统抗凝剂肝素和华法林的局限性促使了用于预防和治疗静脉及动脉血栓栓塞的新型抗凝药物的研发。在简要回顾血栓形成及其调节机制后，本研究聚焦于处于临床试验更高级阶段的新型抗凝剂。
